hyperphosphatemia who have not progressed to dialysis. Therefore it
will not be necessary for the company to file an sNDA for this
indication. A CKD indication will expand the market for sevelamer and
help sustain the long-term growth of the Renal franchise.
-- Sales of Synvisc(R) (hylan G-F 20) and Synvisc-ONE are expected to
reach $270-$280 million this year, compared with $242 million in 2007.
Synvisc-One received CE Mark approval in the European Union in
December. This single-injection regimen has the potential to redefine
the market for viscosupplementation products and expand the benefits of
this therapeutic approach to a broader set of patients by simplifying
osteoarthritis pain management. Genzyme will pursue marketing
approvals for Synvisc-One in Canada, Asia and Latin America based on
the European CE mark approval. Action on a marketing application in
the United States is expected later this year.
-- Transplant revenue is expected to increase to $210-$220 million this
year, compared with $175 million in 2007, driven by increasing global
demand for Thymoglobulin(R) (Anti-thymocyte Globulin [Rabbit]).
Thymoglobulin's growth is being driven by its launch in new geographic
markets and by publications and clinical studies. The product's
growth over the past several quarters has been affected by
manufacturing challenges resulting in stability issues affecting the
appearance of the product. Genzyme has worked closely with the FDA in
addressing these challenges, and has implemented process changes at its
Thymoglobulin manufacturing plant in Lyon, France. These changes have
resulted in improved stability, and Genzyme continues to work to
optimize its processes. The com
|SOURCE Genzyme Corporation|
Copyright©2008 PR Newswire.
All rights reserved